The glutathione-depleting agent buthionine sulfoximine (BSO) was found to be toxic to some AML blast populations. This toxicity was manifested as the appearance of high levels of reactive oxygen generation in GSH-depleted cells, and later by the loss of mitochondrial membrane potential and an increase in intracellular calcium. Striking heterogeneity in BSO sensitivity was observed in a series of four human AML cell lines, and in fresh leukemic blasts obtained from eight AML patients. In some cases, toxicity was seen at BSO concentrations as low as 10 M; approximately 100-fold less than the plasma levels achieved in patients treated with BSO as a drug resistance reversing agent. Based on these results we propose that some AML blast populations are unusually dependent on GSH-based antioxidant mechanisms, due to high intrinsic rates of reactive oxygen generation. The mitochondrial respiratory chain is the most likely source of this reactive oxygen. Because toxicity is seen at clinically achievable concentrations of BSO, this agent might have antileukemic activity in patients.
Introduction
Glutathione (GSH) is the dominant non-protein sulfydryl in cells. 1 It is able to conjugate and detoxify chemically reactive molecules, including alkylating agents and cisplatin, under the action of glutathione S-transferases. 2, 3 Increased cellular GSH content or glutathione S-transferase activity can cause resistance to cytotoxic drugs that directly damage DNA. This type of drug resistance can be reversed by buthionine sulfoximine (BSO), a specific inhibitor of ␥-glutamylcysteine synthetase, the rate limiting enzyme in GSH synthesis. 4, 5 Clinical trials have shown that BSO is well-tolerated at dose schedules that are capable of producing profound depletion in white blood cell and tumor tissue GSH levels. 6, 7 In addition to drug conjugation, GSH protects cells from oxidative stress by reducing hydrogen peroxide and organic peroxides under the action of glutathione peroxidases. 1 Oxidized glutathione (GS-SG) that is formed by this reaction is converted back to GSH by glutathione reductase, using NADPH as the source of metabolic energy. The action of the glutathione redox cycle maintains the overall reducing environment inside cells in the face of oxidizing species that are generated as metabolic byproducts, particularly by the mitochondrial respiratory chain. In this state macromolecules such as lipids and nucleic acids are protected from oxidant damage, and protein sulfydryls are maintained in the reduced state. 8 in part, because they respond to DNA damage by generating reactive oxygen intermediates (ROI). 9 Initially, ara-C-treated cells show a modest increase in reactive oxygen generation associated with an increase in cellular GSH. Then an abrupt transition is seen to a state characterized by very high ROI generation and severe depletion of GSH, indicating the failure of antioxidant defenses and a shift to an oxidizing cellular redox state. 9 We considered that the initial increase in GSH might represent a cellular defense mechanism, able to counter an oxidative stress resulting from DNA damage by ara-C. Therefore we tested whether inhibition of GSH synthesis with BSO might potentiate ara-C toxicity. Unexpectedly, we observed toxicity associated with increased reactive oxygen generation in control cells that were treated with BSO only. For some human AML lines, toxicity, as assessed by clonogenic survival, was seen with BSO concentrations as low as 10 M. This is approximately 100-fold less than the blood concentrations achieved in patients treated with BSO as a drug resistance modulating agent. 6, 7 Similar levels of BSO toxicity were also seen in freshly obtained blasts from AML patients. We propose that inhibition of GSH by BSO disclosed spontaneous ROI production in sensitive blast cells, probably as a byproduct of mitochondrial respiration. If this view is correct, some blast populations survive endogenous ROI production only because of the protection afforded by GSH.
Materials and methods

AML cell lines
The human AML cell lines OCI/AML-1,-2,-4 and -5 were established in our institution, 10, 11 and are maintained in suspension cultures containing ␣-minimal essential medium (␣-MEM) supplemented with 10% fetal calf serum. OCI/AML-2 is growth factor independent, but the other three cell lines require 10% medium conditioned by 5637 bladder carcinoma cells (5637-CM) for optimal growth. 12 
AML patient samples
Clinical samples were obtained from eight patients with high circulating leukemic blast counts according to institutional ethical guidelines. Purified blasts were isolated by a two-step Ficoll-Hypaque centrifugation technique as previously described, 13 counted and resuspended at 1 × 10 6 /ml in 5637-CM supplemented with 10% fetal calf serum and kit ligand as supernatant from COS cells transfected with the gene (obtained courtesy of Genetics Institute, Cambridge, MA, USA). Using the two stage Ficoll-Hypaque procedure, Ͼ90% of the cells obtained are leukemic blasts. Previous work has shown that blasts obtained from the majority of AML patients will grow for up to several weeks in these conditions. 14 Blasts freshly obtained from patients were cultured in suspension for 1-3 days prior to the addition of BSO. Clinical data on the patients are given in Table 1 .
BSO treatment
L-buthionine sulphoximine (Sigma, St Louis, MO, USA) was prepared as a 100 mM solution in water and filter sterilized. It was added to cells in 25 cm 2 flasks during the exponential phase of growth, at a range of concentrations.
Clonogenic assay
Clonogenic blasts were assayed as previously described. 15 Briefly cells from suspension cultures were plated at appropriate concentrations in 96-well linbro plates, with growth medium, growth factors as required and 0.8% methylcellulose. After 4-6 days, colonies containing more than 20 cells are counted with an inverted microscope.
Flow cytometry
Reactive oxygen was measured using dihydrorhodamine 123 (Molecular Probes, Eugene, OR, USA). This is a non-fluorescent reduction product of rhodamine 123 that freely permeates the cell membrane. Inside cells it is oxidized by reactive oxygen intermediates to the brightly fluorescent rhodamine 123. 16 For some experiments, reactive oxygen was also measured using 1 M dichlorofluorescin diacetate (Molecular Probes). Staining was as previously described. 9 Reduced glutathione (GSH) was measured using the sulphydryl probe monobromobimane (MBBr) at a final concentration of 40 M for 5 min, as previously described. 17 This compound binds avidly to glutathione, yielding a brightly fluorescent conjugate. When applied to AML samples, approximately 80% of the fluorescence is derived from the binding of MBBr to GSH, with the remainder coming from other low molecular weight thiols, particularly cysteine. 18 A dual-labelling technique was used to measure ROI and GSH simultaneously. Mitochondrial membrane potential was measured using CMXRos (Molecular Probes), a lipophilic, cationic dye that is concentrated in engergized mitochondria. 19 Cells were stained with a final concentration of 30 nM CMXRos for 30 min at 37°C. Intracellular-free calcium was measured using the fluorescent calcium indicator indo-1, loaded as the acetoxymethyl ester (Molecular Probes) at a final concentration of 3 M at 37°C for 30 min.
Flow cytometry was done using an Epics Elite cell sorter (Coulter, Miami, FL, USA). A 488 nm argon laser was used to excite DHR, DCF and CMXRos. Monobromobimane and indo-1 were excited using a 325 nm HeCd laser. The two lasers were separated with a 40 ms time delay, and the signals processed using a gated amplifier. The following band pass filters were used to collect fluorescence signals: DHR and DCF at 525 nm; CMXRos at 640 nm; MBBr at 450 nm. Electronic ratio measurements of the calcium-bound (405 nm) and calcium-free (525 nm) forms of indo-1 were used to obtain intracellular-free calcium.
Results
In preliminary experiments, we observed that exposure in culture of cells from the AML cell lines to BSO resulted in a doseand time-dependent loss of clonogenic capacity. To examine this effect, cells from four lines, OCI/AML 1, 2, 4 and 5, were exposed to BSO for 48 h at concentrations ranging from 10
M to 10 −3 M; clonogenic cell recovery was measured and GSH content and ROI generation using flow cytometry.
Colony formation
Marked heterogeneity was seen in the sensitivity of AML clonogenic blasts to BSO. The data are shown in Figure 1 as log/log plots of percentage survival of colony-forming cell recovery against BSO concentration. OCI/AML 5 and OCI/AML-2 were resistant with D10 values of 1.09 × 10 
BSO concentration of 10
−5 M; the percentage survival at this concentration is shown as single points in Figure 1 , since no colonies were found in cultures exposed to higher BSO concentrations.
Flow cytometry measurements of GSH and ROI
Cultures exposed to 10 −5 M, 10 −4 M and 10 −3 M BSO were examined by flow cytometry. Cellular GSH content was depleted during exposure to BSO in a time-and concentration-dependent manner. The extent of GSH depletion, shown in Figure 2 , was similar in the cell lines. Since background labelling of other thiols accounts for approximately 20% of the monobromobimane fluorescence signal, 18 these results probably underestimate the true extent of GSH depletion. There was striking heterogeneity in the rates of ROI generation following treatment with BSO for 48 h. This was seen as the emergence of subpopulations showing up to 10-fold higher values than controls. Similar results were obtained using either DHR or DCF as the reactive oxygen probe. As was found using the clonogenic survival assay, these effects on ROI generation were clearly BSO concentration-dependent. This effect was most apparent in OCI/AML-4 cells, which were highly sensitive to BSO as assessed by the clonogenic survival assay, and least apparent in OCI/AML-2 cells, which were also resistant by the clonogenic assay. Figure 3 shows the results for OCI/AML-4 following 24 h BSO, compared to 48 h treatment. Glutathione is replotted on a logarithmic scale to emphasize the accumulation of dead cells in the low GSH/low ROI position following 48 h treatment. Note that ROI generation and toxicity are much less apparent at 24 h, although a population of high ROI cells is apparent at 24 h in the 1 mM BSO sample.
Blasts from patients
Blast cells were obtained as described above from the peripheral blood of eight patients with AML high peripheral blood blast cell counts. When these were exposed to BSO at concentrations from 10 −5 to 10 −3 M for 48 h and then clonogenic cell recovery measured, the results were similar to those seen with the cell lines (Table 2, Figure 4) . Sensitivity varied greatly from patient to patient: some were very sensitive, other resistant and yet others with intermediate levels of kill after BSO. Measurement of GSH and ROI generation using flow cytometry were done using six of the eight patient samples ( Figure 5) . The patterns were similar to those observed with the continuous AML cell lines. Sensitivity as measured in culture by the survival of clonogenic cells, and by ROI generation using flow cytometry, were consistent; cell populations exhibiting high ROI production were also most sensitive by the clonogenic assay (Table 2, Figure 5 ).
Mechanism of BSO toxicity Generation of DNA breaks:
Agents that induce cell death by apoptosis typically produce DNA breaks that can be detected by end labelling using terminal deoxynucleotidyl transferase (TdT). 20 End labelling of BSO-treated leukemic blasts was done using a commercially-available kit (APO-BRDU; Phoenix Flow Systems, San Diego, CA, USA). As shown in Figure 6 , high levels of DNA fragmentation occurred following BSO treatment. Simultaneous measurement of cellular DNA content using propidium iodide showed that this DNA fragmentation occurred in all phases of the cell cycle.
Relationships between ROI, mitochondrial membrane potential and intracellular calcium:
A triple stain flow cytometry method was used to investigate the relationships between reactive oxygen generation, mitochondrial membrane potential and the regulation of intracellular calcium. Figure 7 shows the relation between ROI generation and mitochondrial membrane potential for OCI/AML-4 cells treated with 10 M BSO for 48 h. The high ROI generation is seen in cells that have energized mitochondria, whereas cells with loss of mitochondrial membrane potential show low levels of ROI generation. Therefore the high ROI generation following BSO treatment is not due to the uncoupling of oxidative phosphorylation, as has been reported in modes of apoptosis that involve the mitochondrial permeability transition. 21 Similar patterns were seen with both DHR and DCF as the reactive oxygen probe. Figure 8 shows the correlations between ROI generation and mitochondrial membrane potential with intracellular calcium in BSO-treated OCI/AML-4 cells, using the same data file used to generate Figure 7 . Cells showing loss of mitochondrial membrane potential were found to have elevated intracellular-free calcium, whereas cells showing high ROI generation showed low calcium values. Treatment of the resistant line OCI/AML-2 with 1 mM BSO, an equitoxic concentration, produced virtually identical patterns to those seen in Figures 7  and 8 (not shown).
Effects of phorbol ester on ROI generation:
Mature phagocytic cells can undergo bursts of high ROI generation, due to the action of a phorbol ester-sensitive respiratory burst oxidase system. 22 This respiratory burst has also been reported in some AML cell lines, particularly following treatment with differentiating agents such as retinoic acid. To test whether it could explain the high ROI generation seen following BSO treatment, the rates of DHR oxidation were measured in untreated cells following stimulation with 100 ng/ml phorbol myristate acetate. No increase in fluorescence compared to controls was observed in any of the four cell lines, indicating that the respiratory burst is not functional in these AML lines. Therefore it is unlikely to explain the high ROI production seen following BSO treatment.
Effects of respiratory chain inhibitors on ROI generation:
The mitochondrial respiratory chain is a major site of ROI generation in cells. [23] [24] [25] The most important electron donor in mitochondrial ROI production is believed to be ubisemiquinone, a reduced form of ubiquinone, 26 the electron shuttle between complex I (NADH-CoQ reductase) and complex III (cytochrome reductase). We tested the effects of 2 mM amytal, a complex I inhibitor, and 100 M antimycin A, a complex III inhibitor, on the production of ROI following treatment of OCI/AML-4 cells with 100 M BSO for 48 h. Treatment with amytal resulted in a reduction in ROI production almost to the levels seen in BSO-untreated controls, whereas antimycin A produced increases in ROI generation that were similar in control and BSO-treated cells. These find- ings strongly suggest that the mitochondrial respiratory chain is the source of the increased ROI generation seen following treatment with BSO.
Discussion
Glutathione is present at millimolar concentrations in essentially all mammalian cells. It is involved in numerous biochemical processes such as DNA synthesis and amino acid transport. 1, 27 Recently glutathione has received attention in oncology because of its ability to detoxify reactive cytotoxic drugs such as alkylating agents and platinum compounds, through the action of glutathione S-transferases. 3 Glutathione can also conjugate and detoxify ROIs that are free radicals, such as superoxide and hydroxyl radical. Hydrogen peroxide, an ROI which is not a free radical, is reduced to water by glutathione peroxidase, the resulting oxidized GSH being recycled under the action of glutathione reductase. Metabolic energy is fed into this glutathione redox cycle in the form of NADPH, generated by the pentose phosphate pathway or through the reduction of NADP + by NADH in the mitochondrial matrix space. In addition to hydrogen peroxide, the GSH redox cycle can reduce organic peroxides and disulfide bonds. It plays a dominant role in the maintenance of the overall reducing environment within cells. 1 Reactive oxygen intermediates are generated in the cytoplasm and endoplasmic reticulum by single electron reductions of oxygen. These reactions can occur following cell injury or exposure to redox cycling xenobiotics, and during normal cell processes such as the action of cytochrome P450. [28] [29] [30] [31] Mature neutrophils and macrophages generate high levels of ROI following the phagocytosis of micro-organisms. 22 However, none of the AML lines tested was capable of mounting a respiratory burst in response to phorbol ester. Therefore we consider it unlikely that this mechanism explains the high ROI production seen following BSO treatment.
The mitochondrial respiratory chain is the greatest source of ROI generation in cells. 31 During respiration high energy electrons flow through a series of complexes embedded in the inner mitochondrial membrane. Energy that is given up by these electrons translocates protons across the inner membrane, generating the electrochemical gradient used to drive ATP synthase. The respiratory chain terminates at cytochrome oxidase, where O 2 is fully reduced to water by four electrons. However, 1-2% of all oxygen consumed by the respiratory chain is converted to superoxide as a byproduct. 31, 32 Complex III, which transfers high energy electrons from ubiquinone to cytochrome c, is probably the most important site of single electron reductions of oxygen within the respiratory chain. 26 Amytal, a complex I inhibitor, reduced the rate of ROI generation in BSO-treated cells, whereas inhibition of complex III using antimycin A had the reverse effect. These findings are consistent with the hypothesis that the respiratory chain is the source of the high ROI generation seen in some AML samples following treatment with BSO. Mitochondria detoxify superoxide by dismutation to hydrogen peroxide under the action of manganese superoxide dismutase, followed by the reduction of hydrogen peroxide to water by glutathione peroxidase. Since mitochondria lack catalase activity, they are dependent on glutathione for ROI detoxification. 31 The mitochondrial pool of GSH is resistant to depletion by BSO. 5, 33 However, prolonged treatment results in loss of mitochondrial GSH and oxidative damage to mitochondria. 5, 24, 34, 35 The important novel finding reported here is the unusual sensitivity to BSO observed in some leukemic blast populations. There was a striking heterogeneity in the sensitivity to BSO seen both in established AML cell lines and in fresh patient samples. Flow cytometry showed that sensitive populations underwent apoptosis in a manner that was not cell cycle phase specific. As seen most clearly in Figure 3 , BSO toxicity occurred in stages, with an initial increase in ROI generation, followed by loss of viability as manifested by light scatter changes and propidium iodide uptake. These changes occur asynchronously, resulting in the appearance of the multiple cell populations seen in Figures 2, 3 and 5. Simultaneous measurements of ROI, mitochondrial membrane potential, and intracellular calcium showed that the high levels of ROI were generated in cells maintaining energized mitochondria (boxed population in Figure 7) . Following loss of mitochon-
Figure 5
Correlated dot plots of glutathione content (linear scale) vs log reactive oxygen generation in fresh blasts obtained from AML patients, following 48 h treatment with BSO at the indicated concentrations. Unique patient number is indicated in the top left quadrant of each control panel.
Figure 6
Detection of DNA breaks using end-labelling in OCI/AML-4 cells treated with 100 M BSO for 48 h.
Figure 7
Correlated dot plots of mitochondrial membrane potential vs reactive oxygen in OCI/AML-4 cells treated with 10 M BSO for 48 h. Note that the population of cells with high ROI generation retains mitochondrial membrane potential (boxed).
Figure 8
Correlated dot plots of reactive oxygen (top panels) and mitochondrial membrane potential (bottom panels) vs intracellular ionized calcium. Results obtained from the same data file as in Figure 6 . drial membrane potential ROI generation decreased, probably because cells lose the metobolic energy needed to generate ROI. Therefore the increased ROI production seen with BSO toxicity is not the consequence of the mitochondrial permeability transition, as is seen in other mechanisms of apoptosis 36 and was found in our own recent results examining cytosine arabinoside toxicity in OCI/AML-2 cells. 37 The loss of mitochondrial membrane potential following BSO treatment was a comparatively late event that was associated with increased ionized calcium, an occurrence that has been previously observed following oxidative damage to mitochondria. 38 Possible explanations for the heterogeneity in BSO sensitivity seen in AML include differences in the extent of GSH depletion, and differences in intrinsic rates of mitochondrial ROI generation. Currently we favor the latter explanation, since the extent of whole cell GSH depletion as measured using monobromobimane was similar in sensitive and resistant blast populations. Differences in the rates of mitochondrial ROI production occur between different animal species, and are correlated with the species life span. 25, 39 Furthermore, mitochondrial DNA (mtDNA), which codes for several components of the respiratory chain, is susceptible to damage by mitochondrially generated ROI. 40 , 41 Yakes et al 41 have proposed that this mtDNA damage then produces further inefficiencies in cellular respiration and increases in ROI generation, leading to a downward spiral that eventually causes cell death.
Clinical trials of BSO as an alkylating agent sensitizer have shown this agent to be well-tolerated at dose schedules that can achieve blood BSO concentrations in excess of 1 mM. 6, 42 The results shown here suggest that BSO may have a novel anti-leukemic action related to the development of oxidative stress. Since this effect is seen using concentrations of BSO that can be achieved in patients, we are planning a clinical trial of BSO in patients with refractory AML, using clinical and laboratory end points to assess efficacy.
